Atara Biotherapeutics (ATRA) Change in Receivables (2020 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Change in Receivables came in at -$1.3 million in Q1 2026, down 116.95% YoY from $7.4 million in Q1 2025, and down 89.85% on a QoQ basis from -$660000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Change in Receivables (2020 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 7 years of Change in Receivables data on file, last reported at -$1.3 million in Q1 2026.
- Quarterly Change in Receivables fell 116.95% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.9 million (up 67.08% YoY) and the FY2025 annual result came in at -$229000.0, up 99.3% from the prior year.
- Change in Receivables retreated to -$1.3 million in Q1 2026, from -$660000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $40.0 million in Q4 2022 to a low of -$39.8 million in Q1 2023.
- A 5-year average of -$58000.0 and a median of -$318000.0 in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables jumped 3953.96% — and 2024, when it sank 30474.55%.
- Tracing ATRA's Change in Receivables over 5 years: stood at $40.0 million in 2022, then retreated by 15.08% to $33.9 million in 2023, then sank by 99.57% to $147000.0 in 2024, then tumbled by 548.98% to -$660000.0 in 2025, then tumbled by 89.85% to -$1.3 million in 2026.
- The last three Change in Receivables figures came in at -$1.3 million (Q1 2026), -$660000.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | 318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318,000.00 |
| Jun 30, 2026 | 318,000.00 |
| Mar 31, 2026 | -1.25 Mn |
| Mar 31, 2026 | -1.25 Mn |
| Dec 31, 2025 | -660,000.00 |
| Dec 31, 2025 | -660,000.00 |
| Sep 30, 2025 | 1.91 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | -8.88 Mn |
| Jun 30, 2025 | -8.88 Mn |
| Mar 31, 2025 | 7.39 Mn |
| Mar 31, 2025 | 7.39 Mn |
| Dec 31, 2024 | 147,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Sep 30, 2024 | -1.09 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -33.41 Mn |
| Jun 30, 2024 | -33.41 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |